Literature DB >> 29615434

Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement.

Ching-Jen Chen1, Brian J Sorace2, Aria Shakeri2, Min S Park1, Andrew M Southerland2, Bradford B Worrall2, M Yashar S Kalani1.   

Abstract

Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) has been associated with progressive peripheral arterial disease and, more recently, rare cases of intracranial vascular stenosis have been reported. We report the fourth case of TKI treatment associated intracranial vasculopathy and rapid progression of intracranial vascular stenosis following intracranial stent placement. This was a 49-year-old woman who developed right-sided weakness, paresthesias, numbness, and speech difficulties 7 years following TKI treatment for CML. Cerebral catheter angiography demonstrated 90% stenosis of the left supraclinoid internal carotid artery, for which the patient underwent intracranial stent placement with no residual stenosis and improved distal blood flow. Approximately 1 month following the procedure, the patient returned with similar symptoms. Catheter angiography demonstrated 70% and 50% stenosis just distal and proximal to the stent construct, respectively. Rapid disease progression and non-atherosclerotic vasculopathy may argue against endovascular therapy. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  stenosis; stent; stroke

Mesh:

Substances:

Year:  2018        PMID: 29615434      PMCID: PMC5884258          DOI: 10.1136/bcr-2018-013777

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

Review 1.  Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.

Authors:  Chatree Chai-Adisaksopha; Wilson Lam; Christopher Hillis
Journal:  Leuk Lymphoma       Date:  2015-10-20

Review 2.  Moyamoya disease and moyamoya syndrome.

Authors:  R Michael Scott; Edward R Smith
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

3.  Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

Authors:  Torsten Dahlén; Gustaf Edgren; Mats Lambe; Martin Höglund; Magnus Björkholm; Fredrik Sandin; Anders Själander; Johan Richter; Ulla Olsson-Strömberg; Lotta Ohm; Magnus Bäck; Leif Stenke
Journal:  Ann Intern Med       Date:  2016-06-14       Impact factor: 25.391

4.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Authors:  Karl J Aichberger; Susanne Herndlhofer; Gerit-Holger Schernthaner; Martin Schillinger; Gerlinde Mitterbauer-Hohendanner; Christian Sillaber; Peter Valent
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047

5.  Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.

Authors:  Tomohiko Ozaki; Hajime Nakamura; Nobuyuki Izutsu; Hiroaki Masaie; Jun Ishikawa; Manabu Kinoshita
Journal:  Interv Neuroradiol       Date:  2017-06-05       Impact factor: 1.610

6.  The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state.

Authors:  Naif Alhawiti; Kate L Burbury; Faith A Kwa; Cindy J O'Malley; Peter Shuttleworth; Mohamad Alzard; Abdullah Hamadi; Andrew P Grigg; Denise E Jackson
Journal:  Thromb Res       Date:  2016-07-30       Impact factor: 3.944

7.  Nilotinib treatment-associated cerebrovascular disease and stroke.

Authors:  Elizabeth A Coon; Nicholas L Zalewski; Ernest Matthew Hoffman; Ayalew Tefferi; Kelly D Flemming
Journal:  Am J Hematol       Date:  2013-05-13       Impact factor: 10.047

8.  Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib.

Authors:  Ruham Alshiekh-Nasany; Awss Zidan; Carmen Martinez
Journal:  Clin Case Rep       Date:  2016-11-09

9.  Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.

Authors:  E Hadzijusufovic; K Albrecht-Schgoer; K Huber; G Hoermann; F Grebien; G Eisenwort; W Schgoer; S Herndlhofer; C Kaun; M Theurl; W R Sperr; U Rix; I Sadovnik; B Jilma; G H Schernthaner; J Wojta; D Wolf; G Superti-Furga; R Kirchmair; P Valent
Journal:  Leukemia       Date:  2017-07-31       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.